To order this 250+ page report, which features 140+ figuresand 170+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Inclusions
§ Adetailed assessment of the current market landscape of endocannabinoid systemtargeted therapeutics, providing information on phase of development (clinical,preclinical, and discovery stage) of lead candidates, target therapeutic area(s), route of administration (oral, topical, sublingual, oromucosal, inhalationand others), dosing frequency (once daily, twice daily, thrice daily andothers) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, thechapter includes information on drug developer(s), including information onyear of establishment, company size, and location of headquarters.
§ Elaborateprofiles of prominent endocannabinoid system targeted therapeutics developersthat are engaged in the development of at least four development programs. Eachprofile features a brief overview of the company, its financial information (ifavailable), product portfolio and an informed future outlook.
§ Anin-depth analysis of nearly 600 grants that have been awarded to researchinstitutes engaged in endocannabinoid system targeted projects, in the periodbetween 2016 and 2020 (till January), including analysis based onimportant parameters, such as year of grant award, amount awarded,administration institute centre, funding institute centre, support period, typeof grant application, purpose of grant award, grant mechanism, responsiblestudy section, prominent program officers, and type of recipient organizations.
§ Ananalysis of the partnerships that have been established in the recent past,covering acquisitions, licensing agreements, product development andcommercialization agreements, research agreements, clinical trial agreements,joint venture agreements and other relevant types of deals.
§ Adetailed analysis of the various mergers and acquisitions that have taken placein this domain, highlighting the trend in the number of companies acquiredbetween 2016-2020, based on parameters, such as year of acquisition, type ofacquisition, geographical location of the acquirer and the acquired company,key value drivers, and financial details of the deal (if available). Inaddition, the chapter evaluates the deal multiples of acquisitions specificallyfocused on endocannabinoid system targeted therapeutics, analysing them basedon a number of parameters, namely annual revenues, number of employees and experienceof the acquired company. Moreover, it presents a schematic world maprepresentation of the geographical distribution of this activity, highlightinginter- and intracontinental deals.
§ Aninsightful chessboard analysis highlighting the most popular drug developmentstrategies / paths adopted by various drug developers (with clinicalcandidates) in order to progress their lead drug candidates.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Target Disease Indication
§ Cancer
§ Genetic Disorders
§ Neurological Indications
§ Others
§ Route of Administration
§ Oral
§ Inhalation
§ Key Geographies
§ North America
§ Europe
§ Asia-Pacific and the Rest of the World
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
KeyQuestions Answered
§ Who are the leading industry players in this market?
§ What are the key clinical conditions addressed byendocannabinoid system targeted therapeutics?
§ What are the biological receptors targeted by cannabinoid-basedtherapies?
§ What are the factors that are likely to influence the evolutionof this market?
§ What are the initiatives undertaken by start-ups and big pharmaplayers engaged in this domain?
§ What kind of partnership models are commonly adopted bystakeholders in this industry?
§ How is the current and future market opportunity likely to bedistributed across key market segments?
You may also be interested in thefollowing titles:
1. Neoantigen TargetedTherapies Market, 2019-2030
2. Blood-Brain Barrier(BBB) Market (2nd Edition), 2020-2030: Focus onNon-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific AntibodyTherapeutics Market (4thEdition), 2019-2030
4. ContinuousManufacturing Market (Small Molecules and Biologics),2020 – 2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
